Patents by Inventor Peter C. Gray
Peter C. Gray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240115211Abstract: Disclosed are systems and methods for generating graphical displays of analyte data and/or health information. In some implementations, the graphical displays are generating based on a self-referential dataset that are modifiable based on identified portions of the data. The modified graphical displays can indicate features in the analyte data of a host.Type: ApplicationFiled: December 19, 2023Publication date: April 11, 2024Inventors: Esteban CABRERA, JR., Lauren Danielle ARMENTA, Scott M. BELLIVEAU, Jennifer BLACKWELL, Leif N. BOWMAN, Rian DRAEGER, Arturo GARCIA, Timothy Joseph GOLDSMITH, John Michael GRAY, Andrea Jean JACKSON, Apurv Ullas KAMATH, Katherine Yerre KOEHLER, Paul KRAMER, Aditya Sagar MANDAPAKA, Michael Robert MENSINGER, Sumitaka MIKAMI, Gary A. MORRIS, Hemant Mahendra NIRMAL, Paul NOBLE-CAMPBELL, Philip Thomas PUPA, Eli REIHMAN, Peter C. SIMPSON, Brian Christopher SMITH, Atiim Joseph WILEY
-
Patent number: 11943876Abstract: Pre-connected analyte sensors are provided. A pre-connected analyte sensor includes a sensor carrier attached to an analyte sensor. The sensor carrier includes a substrate configured for mechanical coupling of the sensor to testing, calibration, or wearable equipment. The sensor carrier also includes conductive contacts for electrically coupling sensor electrodes to the testing, calibration, or wearable equipment.Type: GrantFiled: October 23, 2018Date of Patent: March 26, 2024Assignee: DexCom, Inc.Inventors: Jason Halac, John Charles Barry, Becky L. Clark, Chris W. Dring, John Michael Gray, Kris Elliot Higley, Jeff Jackson, David A. Keller, Ted Tang Lee, Jason Mitchell, Kenneth Pirondini, David Rego, Ryan Everett Schoonmaker, Peter C. Simpson, Craig Thomas Gadd, Kyle Thomas Stewart, John Stanley Hayes
-
Patent number: 11931188Abstract: Disclosed are systems and methods for generating graphical displays of analyte data and/or health information. In some implementations, the graphical displays are generating based on a self-referential dataset that are modifiable based on identified portions of the data. The modified graphical displays can indicate features in the analyte data of a host.Type: GrantFiled: September 21, 2021Date of Patent: March 19, 2024Assignee: Dexcom, Inc.Inventors: Esteban Cabrera, Jr., Lauren Danielle Armenta, Scott M. Belliveau, Jennifer Blackwell, Leif N. Bowman, Rian Draeger, Arturo Garcia, Timothy Joseph Goldsmith, John Michael Gray, Andrea Jean Jackson, Apurv Ullas Kamath, Katherine Yerre Koehler, Paul Kramer, Aditya Sagar Mandapaka, Michael Robert Mensinger, Sumitaka Mikami, Gary A Morris, Hemant Mahendra Nirmal, Paul Noble-Campbell, Philip Thomas Pupa, Eli Reihman, Peter C. Simpson, Brian Christopher Smith, Atiim Joseph Wiley
-
Patent number: 9546210Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: GrantFiled: September 21, 2010Date of Patent: January 17, 2017Assignee: Research Development FoundationInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Publication number: 20120141469Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: ApplicationFiled: October 19, 2011Publication date: June 7, 2012Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Publication number: 20120088287Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: ApplicationFiled: October 19, 2011Publication date: April 12, 2012Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Publication number: 20110009319Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: ApplicationFiled: September 21, 2010Publication date: January 13, 2011Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Patent number: 7820620Abstract: Cripto, a developmental oncoprotein, antagonizes activin and TGF-b signaling by forming a complex with activin and TGF-b and their type II receptors. This complex precludes the formation of a functional activin/TGF-b•type II•type I complex, thereby blocking the signaling of activin and TGF-b. Cripto may be generally capable of blocking antiproliferative Smad2/3 signals and provides a novel mechanism of oncogenic action with multiple therapeutic implications. Inhibiting the formation of Cripto and activin/TGF-b complex may enhance antiproliferative effects of activin and TGF-b.Type: GrantFiled: September 14, 2004Date of Patent: October 26, 2010Assignee: Research Development FoundationInventors: Wylie Vale, Craig A. Harrison, Peter C. Gray
-
Publication number: 20100135904Abstract: The present invention provides methods compositions and methods for treating a hyperproliferative disease comprising disrupting Cripto/GRP78 complex formation in a hyperproliferative cell. In certain embodiments, an antibody and/or siRNA may be used to inhibit Cripto/GRP78 binding, optionally coupled with other cancer therapies. Also provided are methods for identifying therapeutic compounds which can selectively inhibit Cripto/GRP78 binding.Type: ApplicationFiled: November 9, 2009Publication date: June 3, 2010Applicant: RESEARCH DEVELOPMENT FOUNDATIONInventors: Peter C. Gray, Gidi Shani, Jonathan A. Kelber, Wylie Vale
-
Patent number: 7455839Abstract: Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-? receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary. The presence of betaglycan within inhibin-responsive tissues and cell types, together with the ability of this protoglycan to bind inhibin and to confer inhibin sensitivity, is consistent with a role of betaglycan as an inhibin-specific receptor mediating inhibin responses within various tissues.Type: GrantFiled: October 29, 2003Date of Patent: November 25, 2008Assignee: Research Development FoundationInventors: Wylie Vale, Kathy A. Lewis, Peter C. Gray, Louise M. Bilezikjian, Amy L. Blount
-
Publication number: 20040258689Abstract: Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-&bgr; receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary.Type: ApplicationFiled: October 29, 2003Publication date: December 23, 2004Applicant: Research Development FoundationInventors: Wylie Vale, Kathy A. Lewis, Peter C. Gray, Louise M. Bilezikjian, Amy L. Blount
-
Patent number: 6692744Abstract: Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-&bgr; receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary.Type: GrantFiled: December 15, 2000Date of Patent: February 17, 2004Assignee: Research Development FoundationInventors: Wylie Vale, Kathy A. Lewis, Peter C. Gray, Louise M. Bilezikjian, Amy L. Blount
-
Publication number: 20010049360Abstract: Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-&bgr; receptor, also functions as an inhibin receptor. Betaglycan augments the binding of inhibin to the ActRII activin receptor. By augmenting inhibin binding to ActRII, betaglycan effectively sequesters ActRII away from activin and thereby reduces activin signaling. In addition, the ActRII-betaglycan complex may generate novel signals distinct from those initiated by activin signaling via ActRII and ALK4. Betaglycan is produced in discrete nuclei of the rat brain and by specific cell types within the adult rat pituitary, testis, and ovary.Type: ApplicationFiled: December 15, 2000Publication date: December 6, 2001Inventors: Wylie Vale, Kathy A. Lewis, Peter C. Gray, Louise M. Bilezikjian, Amy L. Blount